当前位置: 首页 >> 检索结果
781. Norfloxacin modulates the inflammatory response and directly affects neutrophils in patients with decompensated cirrhosis.
作者: Pedro Zapater.;Rocío Caño.;Lucía Llanos.;Antonio J Ruiz-Alcaraz.;Sonia Pascual.;Claudia Barquero.;Rocío Moreu.;Pablo Bellot.;José F Horga.;Carlos Muñoz.;Jara Pérez.;Pilar García-Peñarrubia.;Miguel Pérez-Mateo.;José Such.;Rubén Francés.
来源: Gastroenterology. 2009年137卷5期1669-79.e1页
Patients with cirrhosis undergoing selective intestinal decontamination with norfloxacin show a reduction in serum cytokine levels, probably because of a combined effect of norfloxacin on bowel flora and neutrophils.
782. Phenotypic variation of colonic motor functions in chronic constipation.
作者: Karthik Ravi.;Adil E Bharucha.;Michael Camilleri.;Deborah Rhoten.;Timothy Bakken.;Alan R Zinsmeister.
来源: Gastroenterology. 2010年138卷1期89-97页
Colonic motor disturbances in chronic constipation (CC) are heterogeneous and incompletely understood; the relationship between colonic transit and motor activity is unclear. We sought to characterize the phenotypic variability in chronic constipation.
783. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
作者: Loes van Keimpema.;Frederik Nevens.;Ragna Vanslembrouck.;Martijn G H van Oijen.;Aswin L Hoffmann.;Helena M Dekker.;Robert A de Man.;Joost P H Drenth.
来源: Gastroenterology. 2009年137卷5期1661-8.e1-2页
Therapy for polycystic liver is invasive, expensive, and has disappointing long-term results. Treatment with somatostatin analogues slowed kidney growth in patients with polycystic kidney disease (PKD) and reduced liver and kidney volume in a PKD rodent model. We evaluated the effects of lanreotide, a somatostatin analogue, in patients with polycystic liver because of autosomal-dominant (AD) PKD or autosomal-dominant polycystic liver disease (PCLD).
784. Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy.
作者: Emmanuel Gonzales.;Marie F Gerhardt.;Monique Fabre.;Kenneth D R Setchell.;Anne Davit-Spraul.;Isabelle Vincent.;James E Heubi.;Olivier Bernard.;Emmanuel Jacquemin.
来源: Gastroenterology. 2009年137卷4期1310-1320.e1-3页
Oral bile acid replacement has been shown to be an effective therapy in primary bile acid synthesis defects, but to date there have been no reports of the long-term effects of this therapy. The aim of the study was to evaluate the long-term effectiveness and safety of cholic acid (CA) therapy.
785. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
作者: William J Sandborn.;Paul Rutgeerts.;Brian G Feagan.;Walter Reinisch.;Allan Olson.;Jewel Johanns.;Jiandong Lu.;Kevin Horgan.;Daniel Rachmilewitz.;Stephen B Hanauer.;Gary R Lichtenstein.;Willem J S de Villiers.;Daniel Present.;Bruce E Sands.;Jean Frédéric Colombel.
来源: Gastroenterology. 2009年137卷4期1250-60; quiz 1520页
The efficacy of infliximab for treating patients with ulcerative colitis has been established.
786. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders.
作者: Miguel Saps.;Nader Youssef.;Adrian Miranda.;Samuel Nurko.;Paul Hyman.;Jose Cocjin.;Carlo Di Lorenzo.
来源: Gastroenterology. 2009年137卷4期1261-9页
There are no prospective, multicenter, double-blind, placebo-controlled, randomized pharmacologic trials for the treatment of pain-predominant functional gastrointestinal disorders in children. The aim of this study was to evaluate the efficacy of amitriptyline in children with pain-predominant functional gastrointestinal disorders.
787. Early effects of oral administration of lafutidine with mosapride compared with lafutidine alone on intragastric pH values.
作者: Hiroshi Iida.;Masahiko Inamori.;Yuichi Nozaki.;Hiroki Endo.;Kunihiro Hosono.;Tomoyuki Akiyama.;Yasunari Sakamoto.;Hirokazu Takahashi.;Tomoko Koide.;Chikako Tokoro.;Yasunobu Abe.;Atsushi Nakajima.
来源: BMC Gastroenterol. 2009年9卷52页
The ideal medication for treatment of acid related diseases should have a rapid onset of action to promote hemostasis and resolution of symptoms. The aim of our study was to investigate the inhibitory effects on gastric acid secretion after a single oral administrations of lafutidine, is a newly synthesized H2-receptor antagonist, with mosapride 5 mg or lafutidine alone.
788. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure.
作者: William M Lee.;Linda S Hynan.;Lorenzo Rossaro.;Robert J Fontana.;R Todd Stravitz.;Anne M Larson.;Timothy J Davern.;Natalie G Murray.;Timothy McCashland.;Joan S Reisch.;Patricia R Robuck.; .
来源: Gastroenterology. 2009年137卷3期856-64, 864.e1页
N-acetylcysteine (NAC), an antidote for acetaminophen poisoning, might benefit patients with non-acetaminophen-related acute liver failure.
789. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study.
作者: Subrat Kumar Acharya.;Vikram Bhatia.;Vishnubhatla Sreenivas.;Shankar Khanal.;Subrat Kumar Panda.
来源: Gastroenterology. 2009年136卷7期2159-68页
In acute liver failure (ALF), high blood ammonia levels have been documented that correlate with mortality and complications. L-ornithine L-aspartate (LOLA) reduces ammonia levels by increasing hepatic ammonia disposal and its peripheral metabolism. Present study evaluated efficacy and ammonia lowering effect of LOLA in ALF.
790. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.
作者: Barjesh Chander Sharma.;Praveen Sharma.;Amit Agrawal.;Shiv Kumar Sarin.
来源: Gastroenterology. 2009年137卷3期885-91, 891.e1页
Hepatic encephalopathy (HE) is associated with a poor prognosis. Lactulose is used for the treatment of HE. There is no study on the prevention of recurrence of HE using lactulose.
791. Intra-abdominal pressure alterations after large pancreatic pseudocyst transcutaneous drainage.
作者: Theodossis S Papavramidis.;Vassilis Duros.;Antonis Michalopoulos.;Vassilis N Papadopoulos.;Daniel Paramythiotis.;Nick Harlaftis.
来源: BMC Gastroenterol. 2009年9卷42页
Acute pancreatitis leads to abdominal hypertension and compartment syndrome. Weeks after the episodes pancreatic fluids sometimes organize to pseudocysts, fluid collections by or in the gland. Aims of the present study were to evaluate the intra-abdominal pressure (IAP) induced by large pancreatic pseudocysts and to examine the effect of their transcutaneous drainage on IAP.
792. Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence.
作者: Ashish Kumar.;Sanjeev Kumar Jha.;Praveen Sharma.;Saroj Dubey.;Pankaj Tyagi.;Barjesh Chander Sharma.;Shiv Kumar Sarin.
来源: Gastroenterology. 2009年137卷3期892-901, 901.e1页
Endoscopic variceal ligation (EVL) and propranolol are standard secondary prophylaxis therapies for variceal bleeding. Addition of isosorbide mononitrate (ISMN) to propranolol improves its hemodynamic efficacy; we investigated whether a combination of EVL and propranolol/ISMN was more effective than EVL alone for secondary prophylaxis.
793. Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication.
作者: Jaime N Eisig.;Fernando M Silva.;Ricardo C Barbuti.;Tomás Navarro Rodriguez.;Peter Malfertheiner.;Joaquim P P Moraes Filho.;Schlioma Zaterka.
来源: BMC Gastroenterol. 2009年9卷38页
Increasing resistance to clarithromycin and nitroimidazole is the main cause of failure in the Helicobacter pylori eradication. The ideal retreatment regimen remains unclear, especially in developing countries, where the infection presents high prevalence and resistance to antibiotics. The study aimed at determining the efficacy, compliance and adverse effects of a regimen that included furazolidone, levofloxacin and lansoprazole in patients with persistent Helicobacter pylori infection, who had failed to respond to at least one prior eradication treatment regimen.
794. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial.
作者: James E Everhart.;Anna S Lok.;Hae-Young Kim.;Timothy R Morgan.;Karen L Lindsay.;Raymond T Chung.;Herbert L Bonkovsky.;Marc G Ghany.; .
来源: Gastroenterology. 2009年137卷2期549-57页
With the limited efficacy of current therapy for chronic hepatitis C, modifiable risk factors for liver disease progression are important to identify. Because obesity is associated with liver disease, we examined the effects of weight-related conditions on disease outcomes in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) trial.
795. Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics.
作者: Craig A Friesen.;Nancy A Neilan.;Jennifer V Schurman.;Debra L Taylor.;Gregory L Kearns.;Susan M Abdel-Rahman.
来源: BMC Gastroenterol. 2009年9卷32页
We have previously demonstrated the clinical efficacy of montelukast in a randomized double-blind controlled cross-over trial in patients with dyspepsia in association with duodenal eosinophilia. The mechanism of this clinical response is unknown but could involve a decrease in eosinophil density or activation.
796. Capnographic monitoring of respiratory activity improves safety of sedation for endoscopic cholangiopancreatography and ultrasonography.
作者: Mohammed A Qadeer.;John J Vargo.;John A Dumot.;Rocio Lopez.;Patricia A Trolli.;Tyler Stevens.;Mansour A Parsi.;Madhusudhan R Sanaka.;Gregory Zuccaro.
来源: Gastroenterology. 2009年136卷5期1568-76; quiz 1819-20页
The Joint Commission on the Accreditation of Healthcare Organizations recommends ventilation monitoring during procedural sedation for gastrointestinal endoscopy. We sought to determine whether intervention, based on a microstream capnography-based ventilation monitoring system that has been shown to function as an early warning system for hypoxemia, would decrease hypoxemia during endoscopy.
797. Argon plasma coagulation of cervical heterotopic gastric mucosa as an alternative treatment for globus sensations.
作者: Monther Bajbouj.;Valentin Becker.;Florian Eckel.;Stephan Miehlke.;Oliver Pech.;Christian Prinz.;Roland M Schmid.;Alexander Meining.
来源: Gastroenterology. 2009年137卷2期440-4页
Ablation of gastric inlet patches (GIP) in the cervical esophagus by argon plasma coagulation (APC) can alleviate chronic globus sensations in the throat. We investigated the efficacy of this therapy in a randomized, controlled multicenter trial.
798. Implementation of population screening for colorectal cancer by repeated fecal occult blood test in the Netherlands.
作者: Maaike J Denters.;Marije Deutekom.;Paul Fockens.;Patrick M M Bossuyt.;Evelien Dekker.
来源: BMC Gastroenterol. 2009年9卷28页
Colorectal cancer (CRC) is the third most prevalent type of cancer in the world. Its prognosis is closely related to the disease stage at the time of diagnosis. Early detection of symptomless CRC or precursor lesions through population screening could reduce CRC mortality. However, screening programs are only effective if enough people are willing to participate. This study aims to asses the uptake of a second round of fecal occult blood test (FOBt) based screening and to explore factors that could potentially increase this uptake.
799. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.
作者: Christina Reimer.;Bo Søndergaard.;Linda Hilsted.;Peter Bytzer.
来源: Gastroenterology. 2009年137卷1期80-7, 87.e1页
Rebound acid hypersecretion (RAHS) has been demonstrated after 8 weeks of treatment with a proton-pump inhibitor (PPI). If RAHS induces acid-related symptoms, this might lead to PPI dependency and thus have important implications.
800. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
作者: Càndid Villanueva.;Carles Aracil.;Alan Colomo.;Virginia Hernández-Gea.;Josep M López-Balaguer.;Cristina Alvarez-Urturi.;Xavier Torras.;Joaquim Balanzó.;Carlos Guarner.
来源: Gastroenterology. 2009年137卷1期119-28页
Studies of variceal bleeding have shown that a hemodynamic response to treatment of portal hypertension is appropriate when the hepatic venous pressure gradient (HVPG) decreases below 12 mmHg or by > 20% from baseline. However, in primary prophylaxis, many nonresponders do not bleed and 2 invasive procedures are needed to assess response. We investigated the long-term prognostic value of an acute response to beta-blockers and whether the target reduction in HVPG can be improved in primary prophylaxis.
|